DELYTACT INJECTION use-results comparison survey

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT2033210469

Enrollment

100

Registered

2021-12-04

Start date

2021-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

malignant glioma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: -Delytact injection group : All patients who start receiving DELYTACT during the registration period. -Control group : All patients who were diagnosed as malignant glioma from the day which was 2.5 years before the first injected day of Delytact at the investigational institution to the day before 2 years.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
Overall survival	—

Contacts

Public ContactContact GPSP

Daiichi Sankyo Co.,Ltd.

contact_gpsp@daiichisankyo.co.jp+81-3-6225-1059

Outcome results